表紙
市場調查報告書
商品編碼
409612

醫藥品受託製造機關 (CMO) 產業的定量分析:企業結構,市場規模,市場佔有率,未來展望

PharmSource - Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook - 2019 Edition

出版日期: | 出版商: GlobalData | 英文 42 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球醫藥品 (最終製劑) 用醫藥品受託製造機關 (以下簡稱CMO)的產業趨勢相關分析,提供您CMO的企業數·市場規模·市場佔有率的轉變,及各地區·各領域 (劑型)的分佈趨勢,近來的資本交易趨勢,今後的產業趨勢預測等相關調查。

目錄

  • 摘要整理
  • 產業結構·規模
  • 產業規模和成長率
  • CMO (醫藥品受託製造機關)的市場佔有率
  • 醫藥品CMO產業的未來展望
  • 附錄
  • 市場規模·成長率的估計方法

表格一覽

  • 表格1 CMO的設施收購活動概要 (2012年∼)
  • 表格2 CMO收購 (生物) 製藥企業之生產設施
  • 表格3 CMO收購其他CMO
  • 表格4 退出部分的主要CMO領域
  • 表格5 CMO產業近來的私人股權投資活動
  • 表格6 醫藥品CMO產業的私人股權投資活動 (2011年∼)
  • 表格7 主要CMO的收益額比較 (2012年∼)

圖的一覽

  • 圖1 醫藥品CMO的各地區分佈情形
  • 圖2 醫藥品CMO的明細:不同收益金額 (CMO的數量)
  • 圖3 醫藥品CMO的市場規模 (2009年∼)
  • 圖4 醫藥品CMO的各劑型明細 (以金額為準)
  • 圖5 醫藥品CMO的市場佔有率:不同企業規模
  • 圖6 FDA (美國食品藥物管理局) 的NDA (新藥認證申請書)的認證數量:2010年以後
  • 圖7 全球 (生物) 醫藥品企業的外包化趨勢 (2006年∼)
  • 圖8 FDA的罕見疾病新分子化合物 (NME)的認證數量:2010年以後
  • 圖A1 分析對象企業數的增減
目錄
Product Code: GDPS0027MAR

The motivation for pharma companies outsourcing their manufacturing is often to do with lacking expertise, equipment, or cost reduction (especially for small to mid-sized CMOs) in development of their product's API or dose. For clinical dose manufacturing, there is a high risk associated with the pipeline drug product and as such using a CMO for this mitigates risk for pharma companies that may otherwise have to invest in equipment and facilities.

This report, the 2019 version in this annual series, characterizes the contract dose manufacturing industry along a number of quantitative dimensions, including number and type of participants, market size, market shares of the top CMOs and profitability. We also assess the outlook for the industry. This report is an improvement over previous reports because it utilizes the integration of Dose manufacturing integration into the GlobalData's Pharma Intelligence Center to provide deeper analysis of the industry.

This expert trend report is a comprehensive look at the finished dose contract manufacturing landscape in 2019, including analysis of dose CMO M&A activity, market size and share. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.

Scope

  • This report gives an important expert quantitative analysis on the contract dose manufacturing industry. Findings are based on the industry's most comprehensive database of the dose CMO industry (GlobalDatas Contract Service Providers Database) this analysis is driven by a proprietary model of the dose manufacturing industry, which is continuously updated and refined. The 7 tables and 14 figures throughout the report illustrate major points and trends. This report is required reading for -
  • CMO executives and strategic decision-makers: improves understanding of the dose CMO industry and a critical input for strategic planning efforts.
  • Sourcing and procurement executives in bio/pharmaceutical companies: improving understanding of crucial components of the supply base that will provide insights for supplier selection and management.
  • Private equity investors: they can deeper understanding of the dose CMO market and important insight for identifying potential investment targets.

Reasons to buy

  • What is the geographic reach of Dose CMOs?
  • What are the 2018 revenues generated by Contract dose manufacturing industry?
  • What are the components of revenue change for Contract Dose Manufacturers?
  • What is the breakdown of 2018 revenues by different dosage forms?
  • What are the characteristics of the largest dose CMOs?
  • How did the revenue growth of Contract Dose manufacturers in 2018 compare to Contract API manufacturers? - What is the outlook for the dose CMO industry?
  • What Dose CMO M&A deals occurred in 2018?

Table of Contents

  • List of Tables
  • List of Figures
  • Executive Summary
  • Industry Size and Structure
  • Major Developments Affecting Industry Structure
  • Industry Size and Growth CMO Market Shares
  • Analyzing Recent Dose CMO Industry Performance
  • Appendix

List of Tables

  • Table 1: Summary of CMO Facility Acquisition of Dose Facilities Activity, 2013-2018
  • Table 2: CMO Acquisitions of Dose Manufacturing Facilities, 2018
  • Table 3: Dedicated CMO Acquisitions of Companies with Commercial Dose Capabilities, 2018
  • Table 4: PE Investments in the Dose CMO Industry, 2013-2018
  • Table 5: Percentage of Commercial Dose Facilities that Offer Other Services, by Revenue Tier
  • Table 6: Revenue Composition and Strategic Orientation of Leading CMOs, 2018
  • Table 7: Geographical Reach of Dose CMO Universe, 2018

List of Figures

  • Figure 1: Geographic Reach of the Dose CMO Universe, 2018
  • Figure 2: Geographic Distribution of Commercial Dose Facilities, 2018
  • Figure 3: Geographic Distribution of Commercial Dose Injectable Facilities, 2018
  • Figure 4: Dose CMO Count by Revenue Tiers, 2018
  • Figure 5: Dose CMO Market Size by Revenue, 2009-2018
  • Figure 6: Components of Growth for Dose CMOs, 2017-2018
  • Figure 7: Dose CMO Dosage Form Revenue Segments in 2018 ($B)
  • Figure 8: Headquarters Locations of $0-12M Revenue Tier CMOs
  • Figure 9: Dosage Forms Manufactured for $0-12M Revenue Tier CMOs
  • Figure 10: Dose CMO Industry Market Share by Company Revenue Tier, 2018
  • Figure 11: Bio/Pharma Services Sector Performance
  • Figure 12: Organic Revenue Growth for Public CMOs
  • Figure 13: Mega Cap Outsourcing Propensity 2008-2018
  • Figure 14: Outsourcing of Orphan NMEs 2009-2018